← All stories
Markets
Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening
Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial. The ongoing mRNA cancer vaccine study involves 1,137 pati…
Covered by 1 outlet
All coverage · 1 article